CTI BioPharma Corp. | Ownership
Companies that own CTI BioPharma Corp.
BVF Partners LP
6,929,690
11.95%
0
0.88%
06/30/2018
OrbiMed Advisors LLC
5,000,000
8.61%
0
0.1%
06/30/2018
Stonepine Capital Management LLC
4,049,298
6.98%
-1,092,448
4.38%
06/30/2018
Franklin Advisers, Inc.
3,472,300
5.99%
0
0%
06/30/2018
BlackRock Fund Advisors
2,564,039
4.42%
2,138,492
0%
06/30/2018
The Vanguard Group, Inc.
2,287,968
3.95%
148,104
0%
06/30/2018
Great Point Partners LLC
1,537,020
2.65%
-150,000
0.4%
06/30/2018
Fidelity Management & Research Co.
1,400,000
2.41%
0
0%
06/30/2018
Sphera Funds Management Ltd.
874,407
1.51%
40,774
0.24%
06/30/2018
SSgA Funds Management, Inc.
835,478
1.44%
800,949
0%
06/30/2018
| Address |
3101 Western Avenue
Seattle Washington 98121
United States
|
|
Employees
|
- |
| Website |
http://www.ctibiopharma.com |
| Updated |
07/08/2019 |
| CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. |
